Erasca

Erasca is a clinical-stage precision oncology company based in San Diego, California, whose name encodes its mission: to erase cancer. The company is singularly focused on discovering, developing, and commercializing therapies for cancers driven by RAS and MAPK pathway alterations. According to its official materials, molecular alterations in RAS — described as the most frequently mutated oncogene — and in the MAPK pathway, one of the most frequently altered signaling pathways in cancer, account for approximately five million new patients diagnosed globally each year. Erasca frames the RAS/MAPK pathway as cancer's most commonly mutated signaling cascade, affecting roughly 5.5 million lives annually worldwide. Rather than targeting a single node, Erasca pursues a holistic, modality-agnostic strategy. Its three therapeutic strategies are: targeting upstream and downstream MAPK pathway nodes with single agents and combinations intended to clamp these oncogenic drivers (branded MAPKlamp); targeting RAS, the midstream MAPK pathway node, directly with single agents and combinations; and targeting escape routes enabled by other proteins or pathways to further disrupt RAS/MAPK signaling. The company describes its portfolio as purposefully built to comprehensively — and perhaps synergistically — shut down the pathway. Erasca operates as a public company, publishing stock information, financial information, and investor resources through its website, and it maintains a leadership team, board of directors, and scientific advisory boards. Its pipeline spans multiple programs and clinical trials, and it engages with the scientific community through presentations and publications, including announced presentations at the EORTC-NCI-AACR Symposium. The company also emphasizes a dynamic culture and values, recruiting through a careers section that promotes mission-driven science.

Erasca is a clinical-stage precision oncology company headquartered in San Diego, California. Its name is a contraction of the phrase "erase cancer," reflecting the founding mission that drives the organization. The company was established to address cancers driven by alterations in the RAS/MAPK signaling pathway, which its materials describe as cancer's most commonly mutated pathway, affecting approximately 5.5 million lives each year worldwide, with RAS and MAPK alterations accounting for roughly five million new patients diagnosed globally per year. From its inception, Erasca adopted a holistic, modality-agnostic strategy rather than a single-target approach. The company reasoned that because the RAS/MAPK pathway signals promiscuously, effective shutdown requires targeting not just individual nodes but multiple nodes and cooperative mechanisms in parallel. This led to three therapeutic strategies: targeting upstream and downstream MAPK pathway nodes with single agents and combinations intended to clamp oncogenic drivers (a concept the company brands MAPKlamp); targeting RAS, the midstream node, directly; and targeting escape routes enabled by other proteins or pathways. Erasca has grown into a publicly traded company, publishing stock and financial information and maintaining investor resources. It has built a pipeline of programs and clinical trials, and it engages the scientific and medical communities through presentations and publications, including announced presentations at the 38th EORTC-NCI-AACR Symposium. The company also maintains leadership, board, and advisory structures, and promotes a dynamic culture as part of its recruitment efforts.

• Erasca announces multiple presentations at the 38th EORTC-NCI-AACR Symposium

Clinical-stage precision oncology company pursuing a holistic, modality-agnostic approach to comprehensively shut down the RAS/MAPK pathway.

• MAPKlamp programs

  Single agents and combinations targeting upstream and downstream MAPK pathway nodes to clamp oncogenic drivers.

• Direct RAS-targeting programs

  Single agents and combinations targeting RAS, the midstream MAPK pathway node, directly.

• Escape-route targeting programs

  Therapies targeting escape routes enabled by other proteins or pathways to further disrupt RAS/MAPK signaling.

1. 1Home - Erascaerasca.com
2. 2About - Erascaerasca.com
3. 3Erasca (United States) - Wikidatawikidata.org